

3 September 2025

**Our Ref:** FOI 1298

Dear

**Freedom of Information Act 2000  
Information in Relation to Intravenous Immunoglobulin for the Treatment of  
Myasthenia Gravis**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 22 July 2025. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to the questions you have raised has been provided by the Medicine, Unscheduled Care and Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Olivia Robinson  
Information Governance Officer**

**Q1. Do clinicians in your trust have access to Intravenous Immunoglobulin (IVIg) for the treatment of myasthenia gravis (MG)? (Y/N).**

A1. Yes, clinicians within the Trust have access to IVIg for the treatment of MG.

**Q2. If no, how do clinicians get access to IVIg when treating MG patients who require IVIg treatment?**

A2. Not applicable.

**Q3. How many MG patients received IVIg for MG treatment in the last year?**

A3. The information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

**Q4. Do clinicians in your trust have access to therapeutic plasma exchange (PLEX) for the treatment of myasthenia gravis (MG)? (Y/N).**

A4. No, clinicians within the Trust do not have access to PLEX for the treatment of MG.

**Q5. If no, how do clinicians get access to PLEX when treating MG patients who require PLEX treatment?**

A5. While the Trust does not provide PLEX, referrals can be made to the regional service in the Belfast Health and Social care Trust, in order for clinicians to get access to PLEX when treating MG patients who require PLEX treatment.

**Q6. How many MG patients received PLEX for MG treatment in the last year?**

A6. The information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice in respect of questions 3 and 6.